Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series

References

• Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J. 2019;12(1):100007. doi:10.1016/j.waojou.2018.12.001
   PubMed Web of Science ®Google Scholar
• PubMed – NCBI. Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). Available from: https://www.ncbi.nlm.nih.gov/pubmed/25456708. Accessed December 9, 2019.
   Google Scholar
• Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–858. doi:10.1016/S2213-2600(15)00367-7
   PubMed Web of Science ®Google Scholar
• Zhang JY, Wenzel SE. Tissue and BAL based biomarkers in asthma. Immunol Allergy Clin North Am. 2007;27(4):623–632;vi. doi:10.1016/j.iac.2007.09.003
   Web of Science ®Google Scholar
• PubMed – NCBI. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26793004. Accessed May 18, 2020.
   Google Scholar
• Talini D, Novelli F, Bacci E, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5(1):e005748. doi:10.1136/bmjopen-2014-005748
   PubMed Web of Science ®Google Scholar
• Matucci A, Maggi E, Vultaggio A. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma. Respir Med. 2019;160:105819. doi:10.1016/j.rmed.2019.105819
   PubMed Web of Science ®Google Scholar
• Heffler E, Blasi F, Latorre M, et al. The severe asthma network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7(5):1462–1468. doi:10.1016/j.jaip.2018.10.016
   PubMed Web of Science ®Google Scholar
• Maio S, Baldacci S, Bresciani M, et al. RItA: the Italian severe/uncontrolled asthma registry. Allergy. 2018;73(3):683–695. doi:10.1111/all.13342
   PubMed Web of Science ®Google Scholar
• 2019 GINA Main Report. Global initiative for asthma - GINA. Available from: https://ginasthma.org/gina-reports/. Accessed March 27, 2020.
   Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. Allergy. 2020. doi:10.1111/all.14221
   Web of Science ®Google Scholar
• PubMed - NCBI. Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30425502. Accessed December 9, 2019.
   Google Scholar
• Pelaia C, Calabrese C, Vatrella A, et al. Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma. Biomed Res Int. 2018;2018:4839230. doi:10.1155/2018/4839230
   PubMed Web of Science ®Google Scholar
• Sehmi R, Lim HF, Mukherjee M, et al. Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. J Allergy Clin Immunol. 2018;141(4):1529–1532.e8. doi:10.1016/j.jaci.2018.01.008
   PubMed Web of Science ®Google Scholar
• fasenra-epar-product-information_en.pdf. Available from: https://www.ema.europa.eu/en/documents/product-information/fasenra-epar-product-information_en.pdf. Accessed December 6, 2019.
   Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled Phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Chipps BE, Hirsch I, Trudo F, Alacqua M, Zangrilli JG. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma. Ann Allergy Asthma Immunol. 2020;124(1):79–86. doi:10.1016/j.anai.2019.10.006
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry. Thorax. 2016;71(4):339–346. doi:10.1136/thoraxjnl-2015-207630
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):110–116.e7. doi:10.1016/j.jaci.2017.04.009
   PubMed Web of Science ®Google Scholar
• Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi:10.2147/JAA.S176026
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, FitzGerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59. doi:10.1016/S2213-2600(18)30406-5
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Bourdin A, et al. Two-year integrated efficacy and safety analysis of benralizumab in severe asthma. J Asthma Allergy. 2019;12:401–413. doi:10.2147/JAA.S227170
   PubMed Web of Science ®Google Scholar
• Bourdin A, Shaw D, Menzies-Gow A, et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J Asthma. 2019;1–9. Doi:10.1080/02770903.2019.1705333.
   Web of Science ®Google Scholar
• Jackson D, Roxas C, Thompson L, et al. Real-world oral glucocorticoid-sparing effect of benralizumab in severe asthma. Eur Respir J. 2019;54(suppl 63). doi:10.1183/13993003.congress-2019.PA2527
   Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2020;158:491–500. doi:10.1016/j.chest.2020.08.2083
   PubMed Web of Science ®Google Scholar
• Murphy E, Diaz J, Singh H. P215 real life experience with benralizumab in patients with severe uncontrolled eosinophilic asthma. Ann Allerg Asthma Immunol. 2019;123(5):S36–S37. doi:10.1016/j.anai.2019.08.281
   Web of Science ®Google Scholar
• Tsurumaki H, Matsuyama T, Ezawa K, et al. Rapid effect of benralizumab for hypereosinophilia in a case of severe asthma with eosinophilic chronic rhinosinusitis. Medicina (Kaunas). 2019;55(7). doi:10.3390/medicina55070336
   Web of Science ®Google Scholar
• Pelaia C, Busceti MT, Vatrella A, et al. Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma. SAGE Open Med Case Rep. 2020;8:2050313X20906963. doi:10.1177/2050313X20906963
   PubMed Web of Science ®Google Scholar
• Pelaia C, Busceti MT, Vatrella A, et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm Pharmacol Ther. 2019;58:101830. doi:10.1016/j.pupt.2019.101830
   PubMed Web of Science ®Google Scholar
• Voelker D, Almodallal Y, Scrodin MD, et al. Newer biological agents in the treatment of severe asthma: real-world results from a tertiary referral center. Lung. 2020;198:653–659. doi:10.1007/s00408-020-00369-8
   Web of Science ®Google Scholar
• Kotisalmi E, Hakulinen A, Mäkelä M, Toppila-Salmi S, Kauppi P. A comparison of biologicals in the treatment of adults with severe asthma - real-life experiences. Asthma Res Pract. 2020;6:2. doi:10.1186/s40733-020-00055-9
   Google Scholar
• Izumo T, Tone M, Kuse N, et al. Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study. Ann Transl Med. 2020;8(7):438. doi:10.21037/atm.2020.04.01
   PubMed Web of Science ®Google Scholar
• Pelaia C, Busceti MT, Crimi C, et al. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020;129:110444. doi:10.1016/j.biopha.2020.110444
   PubMed Web of Science ®Google Scholar
• Menzella F, Ruggiero P, Galeone C, Scelfo C, Bagnasco D, Facciolongo N. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma. Pulm Pharmacol Ther. 2020;64:101966. doi:10.1016/j.pupt.2020.101966
   PubMed Web of Science ®Google Scholar
• Di Bona D, Minenna E, Albanesi M, Nettis E, Caiaffa MF, Macchia L. Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: data from a real-life cohort. Pulm Pharmacol Ther. 2020;64:101974. doi:10.1016/j.pupt.2020.101974
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Brussino L, Bonavia M, et al. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med. 2020;171:106080. doi:10.1016/j.rmed.2020.106080
   PubMed Web of Science ®Google Scholar
• Bergantini L, d’Alessandro M, Cameli P, et al. Personalized approach of severe eosinophilic asthma patients treated with mepolizumab and benralizumab. Int Arch Allergy Immunol. 2020;181(10):746–753. doi:10.1159/000508936
   Web of Science ®Google Scholar
• Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504–511.e4. doi:10.1016/j.anai.2018.01.030
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019
   PubMed Web of Science ®Google Scholar
• Gibson PG, McDonald VM. Management of severe asthma: targeting the airways, comorbidities and risk factors. Intern Med J. 2017;47(6):623–631. doi:10.1111/imj.13441
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Wechsler ME, FitzGerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936. doi:10.1183/13993003.00936-2018
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64. doi:10.1016/S2213-2600(17)30344-2
   PubMed Web of Science ®Google Scholar
• Menzella F, Biava M, Bagnasco D, et al. Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? Drugs Context. 2019;8:212580. doi:10.7573/dic.212580
   PubMedGoogle Scholar
• Vetrano DL, Zucchelli A, Bianchini E, et al. Patterns of oral corticosteroids use in primary care patients with severe asthma. Respir Med. 2020;166:105946. doi:10.1016/j.rmed.2020.105946
   PubMed Web of Science ®Google Scholar
• Andersson M, Janson C, Kristensen T, Szende A, Golam S. PRS24 cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden. Value Health. 2019;22:S876–S877. doi:10.1016/j.jval.2019.09.2514
   Web of Science ®Google Scholar
• Crimi C, Ferri S, Crimi N. Bronchiectasis and asthma: a dangerous liaison? Curr Opin Allergy Clin Immunol. 2019;19(1):46–52. doi:10.1097/ACI.0000000000000492
   PubMed Web of Science ®Google Scholar
• Kavanagh J, Roxas C, Thomson L, et al. P89 real-world 1 year effectiveness of benralizumab in severe eosinophilic asthma. Thorax. 2019;74(Suppl2):A138–A138. doi:10.1136/thorax-2019-BTSabstracts2019.232
   Web of Science ®Google Scholar